Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus

PLoS Pathogens

Volumn 8, Issue 12, 2012, Pages

  Mohan, Gopi S ^a   Li, Wenfang ^a,b   Ye, Ling ^a   Compans, Richard W ^a   Yang, Chinglai ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HELA CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNE EVASION; IMMUNIZATION; MICE; MICE, INBRED BALB C; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EBOLA VIRUS; MUS;

EID: 84872010391     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003065     Document Type: Article

References (57)

1. Feldmann H, Geisbert TW, (2011) Ebola haemorrhagic fever. Lancet 377: 849-862.
2. Belyi VA, Levine AJ, Skalka AM, (2010) Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes. PLoS Pathog 6: e1001030.
3. Taylor DJ, Leach RW, Bruenn J, (2010) Filoviruses are ancient and integrated into mammalian genomes. BMC Evol Biol 10: 193.
4. Hayman DT, Emmerich P, Yu M, Wang LF, Suu-Ire R, et al. (2010) Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS One 5: e11978.
5. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, et al. (2009) Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 9: 723-728.
6. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, et al. (2005) Fruit bats as reservoirs of Ebola virus. Nature 438: 575-576.
7. Mohamadzadeh M, Chen L, Schmaljohn AL, (2007) How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 7: 556-567.
8. Falzarano D, Geisbert TW, Feldmann H, (2011) Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 10: 63-77.
9. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177-182.
10. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD, (1998) Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 95: 5762-5767.
11. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST, (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 93: 3602-3607.
12. Volchkov VE, Becker S, Volchkova VA, Ternovoj VA, Kotov AN, et al. (1995) GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214: 421-430.
13. Barrientos LG, Martin AM, Rollin PE, Sanchez A, (2004) Disulfide bond assignment of the Ebola virus secreted glycoprotein SGP. Biochem Biophys Res Commun 323: 696-702.
14. Falzarano D, Krokhin O, Wahl-Jensen V, Seebach J, Wolf K, et al. (2006) Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. Chembiochem 7: 1605-1611.
15. Kindzelskii AL, Yang Z, Nabel GJ, Todd RF 3rd, Petty HR, (2000) Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils. J Immunol 164: 953-958.
16. Volchkova VA, Feldmann H, Klenk HD, Volchkov VE, (1998) The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250: 408-414.
17. Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, et al. (2005) Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 79: 10442-10450.
18. Volchkova VA, Dolnik O, Martinez MJ, Reynard O, Volchkov VE, (2011) Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J Infect Dis 204 Suppl 3: S941-946.
19. Maruyama T, Parren PW, Sanchez A, Rensink I, Rodriguez LL, et al. (1999) Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 179 Suppl 1: S235-239.
20. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, et al. (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73: 6024-6030.
21. Ito H, Watanabe S, Takada A, Kawaoka Y, (2001) Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 75: 1576-1580.
22. Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y, (2001) Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol 75: 2324-2330.
23. Shahhosseini S, Das D, Qiu X, Feldmann H, Jones SM, et al. (2007) Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J Virol Methods 143: 29-37.
24. Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, et al. (2007) Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol 81: 1821-1837.
25. Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF, (2011) Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis 204 Suppl 3: S825-832.
26. Olal D, Kuehne AI, Bale S, Halfmann P, Hashiguchi T, et al. (2012) Structure of an antibody in complex with Its mucin domain linear epitope that is protective against Ebola virus. J Virol 86: 2809-2816.
27. Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, et al. (2011) Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 141: 218-227.
28. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287: 1664-1666.
29. Jacks T, Madhani HD, Masiarz FR, Varmus HE, (1988) Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell 55: 447-458.
30. Wang X, Wong SM, Liu DX, (2006) Identification of Hepta- and Octo-Uridine stretches as sole signals for programmed +1 and -1 ribosomal frameshifting during translation of SARS-CoV ORF 3a variants. Nucleic Acids Res 34: 1250-1260.
31. Ternette N, Tippler B, Uberla K, Grunwald T, (2007) Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25: 7271-7279.
32. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23: 2175-2184.
33. Liliom K, Orosz F, Horvath L, Ovadi J, (1991) Quantitative evaluation of indirect ELISA. Effect of calmodulin antagonists on antibody binding to calmodulin. J Immunol Methods 143: 119-125.
34. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
35. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, et al. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82: 12191-12204.
36. Coll JM, (1995) The glycoprotein G of rhabdoviruses. Arch Virol 140: 827-851.
37. Fazekas de St G, Webster RG, (1966) Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med 124: 331-345.
38. Fazekas de St G, Webster RG, (1966) Disquisitions on Original Antigenic Sin. II. Proof in lower creatures. J Exp Med 124: 347-361.
39. Lin G, Nara PL, (2007) Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res 5: 514-541.
40. Martinez O, Valmas C, Basler CF, (2007) Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology 364: 342-354.
41. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, et al. (2010) Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog 6: e1001098.
42. Brindley MA, Hughes L, Ruiz A, McCray PB Jr, Sanchez A, et al. (2007) Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol 81: 7702-7709.
43. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, et al. (2010) Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 84: 2972-2982.
44. Kaletsky RL, Simmons G, Bates P, (2007) Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol 81: 13378-13384.
45. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM, (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308: 1643-1645.
46. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, et al. (2006) Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80: 4174-4178.
47. Ou W, Delisle J, Jacques J, Shih J, Price G, et al. (2012) Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J 9: 32.
48. Sullivan NJ, Martin JE, Graham BS, Nabel GJ, (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7: 393-400.
49. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3: e177.
50. Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, et al. (2011) A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 5: e1275.
51. Bradfute SB, Warfield KL, Bavari S, (2008) Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol 180: 4058-4066.
52. Kato A, Kiyotani K, Sakai Y, Yoshida T, Nagai Y, (1997) The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J 16: 578-587.
53. Matsuoka Y, Curran J, Pelet T, Kolakofsky D, Ray R, et al. (1991) The P gene of human parainfluenza virus type 1 encodes P and C proteins but not a cysteine-rich V protein. J Virol 65: 3406-3410.
54. Wen Z, Ye L, Gao Y, Pan L, Dong K, et al. (2009) Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res 84: 215-224.
55. Blasco R, Moss B, (1995) Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158: 157-162.
56. Ye L, Lin J, Sun Y, Bennouna S, Lo M, et al. (2006) Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 351: 260-270.
57. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.